Anne Sumbul

2.1k total citations · 1 hit paper
17 papers, 1.1k citations indexed

About

Anne Sumbul is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Anne Sumbul has authored 17 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 13 papers in Oncology and 4 papers in Immunology. Recurrent topics in Anne Sumbul's work include Lymphoma Diagnosis and Treatment (13 papers), CAR-T cell therapy research (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Anne Sumbul is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), CAR-T cell therapy research (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Anne Sumbul collaborates with scholars based in United States, Canada and Spain. Anne Sumbul's co-authors include Philippe Armand, Stephen M. Ansell, Jonathon B. Cohen, Margaret A. Shipp, John M. Timmerman, Kazunobu Kato, Kerry J. Savage, Marek Trněný, Radhakrishnan Ramchandren and Scott J. Rodig and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Anne Sumbul

17 papers receiving 1.1k citations

Hit Papers

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphom... 2018 2026 2020 2023 2018 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
    2018 455 citations Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology profile →

Peers

Anne Sumbul
Margaretha G.M. Roemer Netherlands
Sarah E. Daadi United States
Won-Seog Kim South Korea
Courtney Connelly United States
Won-Seog Kim South Korea
Santiago Mercadal Spain
Jocelyn Maragulia United States
Neha Mehta–Shah United States
TC Greiner United States
Shinichi Makita Japan
Margaretha G.M. Roemer Netherlands
Anne Sumbul
Citations per year, relative to Anne Sumbul Anne Sumbul (= 1×) peers Margaretha G.M. Roemer

Countries citing papers authored by Anne Sumbul

Since Specialization
Citations

This map shows the geographic impact of Anne Sumbul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Sumbul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Sumbul more than expected).

Fields of papers citing papers by Anne Sumbul

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Sumbul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Sumbul. The network helps show where Anne Sumbul may publish in the future.

Co-authorship network of co-authors of Anne Sumbul

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Sumbul. A scholar is included among the top collaborators of Anne Sumbul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Sumbul. Anne Sumbul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Habib, Ali A., Kristl G. Claeys, Vera Bril, et al.. (2025). ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis. Annals of Clinical and Translational Neurology. 12(6). 1162–1170. 2 indexed citations
2.
Bril, Vera, Ali A. Habib, Kristl G. Claeys, et al.. (2024). Fixed Cycle and Q2W Dosing of Intravenous Efgartigimod for gMG: Part A of ADAPT NXT. Neurology. 103(7_Supplement_1). 1 indexed citations
3.
Bril, Vera, Yessar Hussain, Kelly Gwathmey, et al.. (2024). Fixed-cycle and Continuous Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Study Design of ADAPT NXT (P10-11.010). Neurology. 102(7_supplement_1). 3 indexed citations
4.
Armand, Philippe, Ann Janssens, Giuseppe Gritti, et al.. (2020). Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 137(5). 637–645. 70 indexed citations
5.
Ansell, Stephen M., Monique C. Minnema, Peter Johnson, et al.. (2019). Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology. 37(6). 481–489. 249 indexed citations
6.
Ramchandren, Radhakrishnan, Eva Domingo‐Doménech, Antonio Rueda, et al.. (2019). Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. Journal of Clinical Oncology. 37(23). 1997–2007. 160 indexed citations
7.
Ansell, Stephen M., Eva Domingo‐Doménech, A. Rueda, et al.. (2019). NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED‐STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2‐YEAR FOLLOW‐UP. Hematological Oncology. 37(S2). 146–147. 9 indexed citations
8.
9.
Armand, Philippe, Andreas Engert, Anas Younes, et al.. (2018). Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. Journal of Clinical Oncology. 36(14). 1428–1439. 455 indexed citations breakdown →
10.
11.
Ramchandren, Radhakrishnan, Michelle A. Fanale, Antonio Rueda, et al.. (2017). Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study. Blood. 130(Suppl_1). 651–651. 22 indexed citations
12.
Fanale, Michelle A., Andreas Engert, Anas Younes, et al.. (2017). NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL. Hematological Oncology. 35(S2). 135–136. 12 indexed citations
13.
Armand, Philippe, Pier Luigi Zinzani, Graham P. Collins, et al.. (2016). Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma. Blood. 128(22). 3502–3502. 18 indexed citations
14.
Armand, Philippe, Margaret A. Shipp, John Kuruvilla, et al.. (2016). A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.. Journal of Clinical Oncology. 34(15_suppl). TPS7573–TPS7573. 4 indexed citations
15.
Timmerman, John M., Andreas Engert, Anas Younes, et al.. (2016). Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Blood. 128(22). 1110–1110. 34 indexed citations
16.
Zinzani, Pier Luigi, Andreas Engert, Ahmed Younes, et al.. (2016). CHECKMATE 205 COHORT C: NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AFTER PRIOR BRENTUXIMAB VEDOTIN AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION. Kölner Universitäts PublikationsServer (Universität zu Köln). 1 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Margaretha G.M. Roemer Breakdown of academic impact, for papers by Sarah E. Daadi Breakdown of academic impact, for papers by Won-Seog Kim Breakdown of academic impact, for papers by Courtney Connelly Breakdown of academic impact, for papers by Won-Seog Kim Breakdown of academic impact, for papers by Santiago Mercadal Breakdown of academic impact, for papers by Jocelyn Maragulia Breakdown of academic impact, for papers by Neha Mehta–Shah Breakdown of academic impact, for papers by TC Greiner Breakdown of academic impact, for papers by Shinichi Makita
Rankless by CCL
2026